Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

efatutazone 1Nivolumab 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Non-small Cell Lung Cancer (NSCLC) × Clear all
NCT07590531 2026-05-15

AMT-116 in Combination With Ivosidan in Patients With Lung Cancer

Multitude Therapeutics Inc.

Phase 1/2 Not yet recruiting
118 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer (NSCLC)

NCT02175017 2024-12-09

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Ono Pharmaceutical Co., Ltd.

Phase 2 Completed
104 enrolled 21 charts
Thoracic

Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01101334 2020-06-16

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Completed
90 enrolled 11 charts
Thoracic

Advanced Non-small Cell Lung Cancer (NSCLC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡